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ABSTRACT
Background
Treatment with glucocorticoids is associated with bone loss starting soon after ther-
apy is initiated and an increased risk of fracture.
Methods
We performed a randomized, double-placebo, double-blind clinical trial of 18 months’ 
duration among patients with a rheumatic disease who were starting glucocorticoids 
at a daily dose that was equivalent to at least 7.5 mg of prednisone. A total of 201 
patients were assigned to receive either alendronate (10 mg) and a placebo capsule of 
alfacalcidol daily or alfacalcidol (1 μg) and a placebo tablet of alendronate daily. The 
primary outcome was the change in bone mineral density of the lumbar spine in 18 
months; the secondary outcome was the incidence of morphometric vertebral defor-
mities.
Results
A total of 100 patients received alendronate, and 101 received alfacalcidol; 163 patients 
completed the study. The bone mineral density of the lumbar spine increased by 2.1 
percent in the alendronate group (95 percent confidence interval, 1.1 to 3.1 percent) 
and decreased by 1.9 percent in the alfacalcidol group (95 percent confidence inter-
val, –3.1 to –0.7 percent).  At 18 months, the mean difference of change in bone min-
eral density between the two groups was 4.0 percent (95 percent confidence inter-
val, 2.4 to 5.5 percent). Three patients in the alendronate group had a new vertebral 
deformity, as compared with eight patients in the alfacalcidol group (of whom three 
had symptomatic vertebral fractures) (hazard ratio, 0.4; 95 percent confidence inter-
val, 0.1 to 1.4).
Conclusions
During this 18-month trial in patients with rheumatic diseases, alendronate was more 
effective in the prevention of glucocorticoid-induced bone loss than was alfacalcidol. 
(ClinicalTrials.gov number, NCT00138983.)
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G
lucocorticoids are frequently 
used in patients with rheumatic diseases 
and are associated with increased bone 
loss and a risk of fracture.1-3 An important effect of 
glucocorticoids on bone is the inhibition of bone 
formation by decreasing the number of osteoblasts 
and hampering their function.4,5 Glucocorticoids 
also increase the rate of bone resorption by stim-
ulating the formation and action of osteoclasts. 
Furthermore, glucocorticoids decrease intestinal 
absorption of calcium and increase renal calcium 
excretion.5-8 Although daily doses of prednisone of 
7.5 mg or more have been associated with gluco-
corticoid-induced osteoporosis,9,10 lower doses of 
the drug have also been linked to such changes.11 
Active vitamin D3 analogues, such as calcitriol and 
alfacalcidol, stimulate the formation and action of 
osteoblasts,12 leading to increased bone forma-
tion.13 These agents prevent bone loss and reduce 
the risk of vertebral fracture during glucocorticoid 
therapy.14-16
Bisphosphonates induce apoptosis of osteo-
clasts and inhibit bone resorption.17 Alendronate, 
one of the bisphosphonates, is effective in the pre-
vention and treatment of glucocorticoid-induced 
osteoporosis.18-20 In an open-label study involv-
ing patients with a rheumatic disease who were 
either receiving or starting treatment with glu-
cocorticoids, alendronate was more effective than 
calcitriol in the preservation of bone.21 In renal-
transplant recipients, alendronate combined with 
calcitriol was superior to calcitriol alone in the 
prevention of bone loss during glucocorticoid 
therapy.22,23 Recent studies showed that alendro-
nate and calcitriol were equally effective in the 
prevention of glucocorticoid-induced osteoporosis 
in patients with a renal or cardiac transplant.24,25 
We compared the effects of alfacalcidol and alen-
dronate in patients with a rheumatic disease who 
were receiving glucocorticoids.
Methods
Study Design
During our 18-month, double-blind, double-place-
bo–controlled study, we enrolled 201 patients of all 
racial and ethnic groups between the ages of 18 
and 90 years who had a rheumatic disease and ei-
ther were starting glucocorticoid therapy or had 
begun glucocorticoid therapy within the previous 
12 weeks at a daily dose of at least 7.5 mg of pred-
nisone or its equivalent. The anticipated duration 
of glucocorticoid treatment was six months or more 
for all patients.
Exclusion criteria were glucocorticoid treatment 
for longer than the previous 12 weeks; therapy 
with hormone-replacement agents, anabolic ste-
roids, calcitonin, active vitamin D3 analogues, 
fluoride, or bisphosphonates during the previous 
12 months; or the presence of primary hyperpara-
thyroidism, hyperthyroidism, or hypothyroidism 
in the year before the study began. Patients who 
were pregnant or breast-feeding were excluded, as 
were patients with metabolic bone diseases, docu-
mented hypocalcemia or hypercalciuria, a creati-
nine clearance of less than 50 ml per minute, or a 
history of nephrolithiasis during the previous five 
years.
After patients had provided written informed 
consent, they were randomly assigned to receive 
oral treatment with either alendronate (10 mg) and 
a look-alike placebo capsule of alfacalcidol or alfa-
calcidol (1 μg) and a placebo tablet of alendronate, 
all once daily. Because of ethical considerations, 
an untreated control group was not included in 
this study. A person in the pharmacy of the coor-
dinating center who was not otherwise involved 
in the study performed the stratified randomiza-
tion with a concealed, computer-generated ran-
domization procedure. Patients were stratified 
according to the initial daily dose of glucocorti-
coids they received (≤15 mg or >15 mg), sex, age 
(≤50 years or >50 years), and the presence or ab-
sence of morphometric vertebral deformities at 
baseline.
The outpatient clinics of 23 departments of 
rheumatology in the Netherlands referred 210 pa-
tients for screening during an 18-month enroll-
ment period. The medical ethics committees of all 
participating centers approved the study protocol. 
Of the 210 eligible patients (Fig. 1), 9 declined to 
participate. The first patient started treatment with 
a study medication in May 2000, and the last pa-
tient finished the study in October 2003. Patients 
were seen three weeks before the start of the study, 
the day study medication was started (baseline), 
and subsequently every third month. At baseline, 
the intake of dietary calcium was estimated with 
a questionnaire, the type of rheumatic disease was 
noted, and inclusion and exclusion criteria were 
checked. Patients with a dietary intake of less than 
1000 mg of calcium per day received a tablet that 
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contained 500 mg of elemental calcium per day. 
Patients with a deficiency of 25-hydroxyvitamin D 
(defined by a serum level of <30 nmol per liter) 
received 400 IU of cholecalciferol per day. At each 
visit, any change in the glucocorticoid dose was 
recorded. Patients were asked about back pain, and 
the occurrence of any nonvertebral fracture was 
recorded.
The primary efficacy end point was the percent 
change in bone mineral density of the lumbar 
spine (lumbar vertebrae 2 through 4) at 18 months. 
Secondary efficacy end points were the percent 
change in bone mineral density of the femoral 
neck and total hip at 18 months and the incidence 
of morphometric vertebral deformities, symptom-
atic vertebral fractures, and nonvertebral fractures.
Measurement of Bone Mineral Density
Bone mineral density of the lumbar spine, femoral 
neck, and total hip was measured at baseline and 
at 6, 12, and 18 months with dual-energy x-ray ab-
sorptiometry (DEXA); 11 centers used Hologic ma-
chines (Hologic), and 12 centers used Lunar ma-
chines (General Electric). Bone mineral density was 
expressed as grams per square centimeter, and 
T scores and z scores were calculated separately 
for Hologic and Lunar machines.
Radiographic Analysis
Radiography of the lateral lumbar and thoracic 
spine was performed at baseline and at 18 months 
and at any time during the study in patients with 
new back pain. All radiographs were centrally as-
sessed in a blinded fashion by two trained observ-
ers, the corresponding author and one independent 
reader, according to the method of Kleerekoper 
et al.26 This method consists of visual inspection 
of the spine from thoracic vertebra 4 through lum-
bar vertebra 5, comparing each vertebra with those 
below and above. If an abnormally shaped verte-
bra is identified, the anterior, middle, and poste-
rior heights of this vertebra are measured with a 
ruler and scored as follows: 1 (only end-plate defor-
mity, with a middle height of less than 85 percent), 
2 (an anterior-wedge deformity, with an anterior 
height of less than 85 percent), or 3 (a compression 
deformity, with all three heights of less than 85 
percent); a score of 0 denotes normal shape and 
dimensions. A new vertebral deformity on a radio-
graph that was obtained because of new back pain 
was defined as a symptomatic vertebral fracture. 
Nonvertebral fractures were confirmed by radiog-
raphy.
Biochemical Measurement
Serum for measurement of calcium, creatinine, 
and albumin was collected at baseline and at 1, 2, 
3, 6, 9, 12, 15, and 18 months and was analyzed 
at the laboratory of each participating center. 
Standardization of the data was done through a 
conversion method, according to the chemistry 
laboratory protocol of Covance Virtual Central Lab-
oratory in Zeist, the Netherlands, where data were 
centrally pooled. Calcium was corrected for serum 
albumin according to the following formula: cal
cium + [(40 − albumin) × 0.02].27 Because of logis-
tic problems in this multicenter trial, 24-hour mea-
surement of urinary calcium was not performed. 
At baseline, serum 25-hydroxyvitamin D was mea-
sured and analyzed by radioimmunoassay at a cen-
tral laboratory. Measurement of serum intact para-
201 Underwent randomization
210 Patients eligible
9 Declined
participation
100 Assigned
to alendronate
21 Withdrew
1 at 0 mo
6 at 3 mo
4 at 6 mo
4 at 9 mo
3 at 12 mo
3 at 15 mo
79 Analyzed
at 18 mo
101 Assigned
to alfacalcidol
17 Withdrew
6 at 3 mo
5 at 6 mo
2 at 9 mo
1 at 12 mo
3 at 15 mo
84 Analyzed
at 18 mo
Figure 1. Enrollment and Outcomes.
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thyroid hormone was performed at baseline and 
at 1, 2, 3, and 18 months by chemiluminescence 
immunoassay; serum carboxy-terminal propep-
tide of type 1 procollagen (P1CP) was measured 
at baseline and at 6, 12, and 18 months by radio-
immunoassay; and fasting (second void) urinary 
N-telopeptide was measured at baseline and 3, 6, 
9, 12, 15, and 18 months by enzyme-linked im-
munosorbent assay. Bone-marker samples were 
collected in the morning and stored at −70°C at a 
central laboratory for batch analyses.
Safety Criteria and Adverse Events
At each visit, all adverse events were recorded and 
the relation of the event with the study drugs 
scored as “no relation,” “possible,” “probable,” or 
“definite.” The severity of the event was scored as 
mild, moderate, or severe. Hypercalcemia was de-
fined as a serum calcium level corrected for albu-
min of more than 2.7 mmol per liter and hypocal-
cemia as a corrected level of less than 2.2 mmol 
per liter. If hypercalcemia occurred in patients who 
were receiving supplemental calcium or cholecal-
ciferol, the supplementation was discontinued. If 
hypercalcemia persisted at a second check two 
weeks later, the dose of either alfacalcidol or pla-
cebo was reduced to once every two days until the 
end of the study. This dose reduction was the first 
step in patients who were not receiving supple-
mental calcium or cholecalciferol in case of hyper-
calcemia. If hypercalcemia still persisted after two 
weeks of a reduced dose of trial medication, the 
trial medication was stopped and the patient con-
tinued to be followed.
Statistical Analysis
Given a two-sided alpha level of 0.05, the study had 
a statistical power of 80 percent to detect a mean 
(±SD) difference between the two groups in bone 
mineral density of 5±6 percent after 18 months, 
assuming that 200 patients were enrolled and that 
40 percent of patients were lost to follow-up. Re-
peated-measures analysis of differences between 
the two groups in changes from baseline in bone 
mineral density were performed with the use of 
model-based restricted maximum-likelihood esti-
mates of the means according to group, to include 
all available data. Differences between the treat-
ment groups in continuous biochemical variables 
were tested for significance at 18 months with a 
two-sample t-test or Mann–Whitney U test as ap-
propriate.
Efficacy and safety analyses included all pa-
tients for whom data on bone mineral density were 
available, regardless of whether they were still re-
ceiving study medication. Ordinal data were tested 
with the use of the chi-square test. Proportional-
hazards regression analysis was used to adjust for 
the difference in the number of vertebral defor-
mities in the two treatment groups at baseline. 
Hazard ratios were calculated for differences in 
the incidence of vertebral and nonvertebral frac-
tures and of hypercalcemia between the two treat-
ment groups. All tests were two-sided, and all 
analyses were performed at the coordinating hos-
pital, the University Medical Center Utrecht, in 
Utrecht, the Netherlands.
Results
Baseline characteristics and bone mineral den-
sity of the two groups are shown in Table 1. The 
mean daily glucocorticoid doses during the study 
were 11.8±8.8 mg in the alendronate group and 
11.1±7.3 mg in the alfacalcidol group, a difference 
of 0.7 mg per day (95 percent confidence interval, 
−1.6 to 3.0), and the mean cumulative glucocorti-
coid doses were 5790±3663 mg and 5704±3375 mg, 
respectively, a difference of 86 mg (95 percent con-
fidence interval, −899 to 1070).
Withdrawal from the study
In the alendronate group, one patient died of a per-
forated sigmoid colon due to diverticulitis and 
another died from newly discovered non-Hodg-
kin’s lymphoma. In the alfacalcidol group, one pa-
tient died from a stroke. Before the 18-month visit, 
19 patients in the alendronate group withdrew (1 
before starting alendronate) and 2 died, and 16 
withdrew in the alfacalcidol group and 1 died, 
accounting for rates of retention of 79 and 83 per-
cent, respectively. Reasons for discontinuation in 
the two groups were lack of motivation in eight 
patients in the alendronate group and seven in 
the alfacalcidol group; gastrointestinal side effects 
in five and two, respectively; cancer in two and one, 
respectively; and other conditions in three and six, 
respectively. None of these differences was sig-
nificant. At 18 months, bone mineral density of 
the lumbar spine was measured in 79 patients in 
the alendronate group and 84 in the alfacalcidol 
group; bone mineral density of the femoral neck 
was measured in 73 and 70 patients, respectively; 
and bone mineral density of the total hip was mea-
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Table 1. Baseline Characteristics and Bone Mineral Densities of the Patients.*
Variable
Alendronate
(N = 99)
Alfacalcidol
(N = 101)
Age — yr 60±14 62±15
Female sex — no.
Premenopausal 7 10
Postmenopausal 52 55
Race or ethnic group — no.†
White 93 87
Black 2 6
Other 4 8
Dose of glucocorticoid (prednisone 
equivalent) — mg/day
23±20 22±18
Serum 25-hydroxyvitamin D level 
<30 nmol/ml — no.
19 21
Dietary calcium intake — mg/day 947±357 996±330
Calcium supplementation — no. 58 56
Height — cm 169±10 169±9
Weight — kg 74±13 73±12
Vertebral deformity — no. 6 14
Diagnosis — no. 
Polymyalgia rheumatica 36 36
Rheumatoid arthritis 33 41
Other 30 24
Hologic System
(N = 55)
Lunar System
(N = 44)
Hologic System
(N = 58)
Lunar System
(N = 43)
Site of bone mineral density 
measurement
Lumbar spine (L2–L4)
Mean — g/cm2 0.99±0.17 1.15±0.23 1.02±0.16 1.19±0.23
T score −0.91±1.55  −0.38±1.85 −0.71±1.45 −0.06±1.92
z score 0.05±1.54 0.39±1.59 0.42±1.51 0.75±1.69
Femoral neck
Mean — g/cm2 0.78±0.14 0.89±0.16 0.79±0.15 0.88±0.15
T score −1.40±1.15 −0.79±1.41 −1.23±1.28 −0.98±1.30
z score −0.07±0.96 0.12±0.97 0.11±1.13 0.09±1.10
Total hip
Mean — g/cm2 0.91±0.16 0.95±0.16 0.89±0.13 0.90±0.13
T score −0.79±1.18 −0.70±1.22 −0.89±1.09 −1.05±1.03
z score 0.09±1.06 0.13±0.88 0.02±1.09 −0.03±1.00
* Plus–minus values are means ±SD. There were no significant differences between the two groups. The T score expresses 
the patient’s bone mineral density as the number of SDs above or below the mean bone mineral density of young 
adults of the same sex and race, and the z score, the number of SDs above or below the mean bone mineral density 
of control persons of the same age, sex, and race.
† Race or ethnic group was designated by the investigators. 
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sured in 61 and 52 patients, respectively. At 18 
months, three of the patients who had withdrawn 
from the alendronate group, but none who had 
withdrawn from the alfacalcidol group, under-
went measurement of bone mineral density and 
laboratory tests. 
Changes in Bone Mineral Density
After 18 months, the mean bone mineral density 
of the lumbar spine had increased by 2.1 percent 
in the alendronate group (95 percent confidence 
interval, 1.1 to 3.1 percent) and decreased by 1.9 
percent in the alfacalcidol group (95 percent con-
fidence interval, –3.1 to −0.7 percent), an absolute 
difference between the two groups of 4.0 percent 
(95 percent confidence interval, 2.4 to 5.5 percent) 
(Fig. 2A). The bone mineral density of the femo-
ral neck had increased by 1.4 percent in the alen-
dronate group (95 percent confidence interval, 
0.1 to 2.7 percent) and decreased by 2.0 percent in 
the alfacalcidol group (95 percent confidence in-
terval, −3.7 to –0.3 percent), an absolute difference 
of 3.4 percent (95 percent confidence interval, 1.3 
to 5.5 percent) (Fig. 2B). The bone mineral den-
sity of the total hip had increased by 0.8 percent 
in the alendronate group (95 percent confidence 
interval, −0.7 to 2.2 percent) and decreased by 2.2 
percent in the alfacalcidol group (95 percent con-
fidence interval, −4.0 to –0.5 percent), an absolute 
difference of 3.0 percent (95 percent confidence 
interval, 0.8 to 5.2 percent) (Fig. 2C). The treat-
ment effect was significant for the primary efficacy 
end point (P<0.001 by repeated-measures analysis).
Incidence of Vertebral Deformities 
and Nonvertebral Fractures
In the alendronate group, three patients had a new 
vertebral deformity. In the alfacalcidol group, eight 
patients had 13 new vertebral deformities (of which 
5 were symptomatic in three patients); the hazard 
ratio for vertebral deformities in the alendronate 
group as compared with the alfacalcidol group was 
0.4 (95 percent confidence interval, 0.1 to 1.4). 
Adjustment for the number of vertebral fractures 
at baseline also yielded a hazard ratio of 0.4 (95 
percent confidence interval, 0.1 to 1.4). In either 
group, only one of the patients with a new verte-
bral deformity had a deformity at baseline.
In the alendronate group, two patients had 
fractures: one of the midfoot and another of the 
forearm. In the alfacalcidol group, three patients 
had fractures: one of the femoral neck, one of the 
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Figure 2. Changes in Bone Mineral Density Associated 
with Alendronate and Alfacalcidol from Baseline 
to 18 Months.
At 18 months, the mean difference in bone mineral 
density (BMD) between the alendronate and alfacal-
cidol groups was 4.0 percent (95 percent confidence 
  interval, 2.4 to 5.5 percent) for the lumbar spine 
(Panel A), 3.4 percent (95 percent confidence interval, 
1.3 to 5.5 percent) for the femoral neck (Panel B), and 
3.0 percent (95 percent confidence interval, 0.8 to 5.2 
percent) for the total hip (Panel C). The I bars repre-
sent SE.
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pubic bone, and one of a rib; the hazard ratio for 
nonvertebral fracture in the alendronate group 
as compared with the alfacalcidol group was 0.7 
(95 percent confidence interval, 0.1 to 4.0).
Laboratory Measurements
At 18 months, the difference between the alendro-
nate group and the alfacalcidol group in the change 
from baseline in serum calcium level was −0.24 mg 
per deciliter (−0.06 mmol per liter) (95 percent con-
fidence interval, −0.44 to −0.08 [−0.11 to −0.02]) 
(Fig. 3A). The difference between groups in the 
change from baseline in the serum creatinine lev-
el was −0.03 mg per deciliter (−2.6 μmol per liter) 
(95 percent confidence interval, 0.08 to 0.03 [−7.5 
to 2.3]). The difference between groups in the 
change from baseline in the serum parathyroid 
hormone level was 2.4 pmol per liter (95 percent 
confidence interval, 1.7 to 3.1) (Fig. 3B). The dif-
ference between groups in the change from base-
line in the serum P1CP level was −400 pmol per 
liter (95 percent confidence interval, −568 to −111) 
(Fig. 3C). The difference between groups in the 
change from baseline in the urinary N-telopeptide 
level was −22 nmol per liter (95 percent confidence 
interval, −146 to 101) (Fig. 3D).
Adverse Events
Table 2 lists the adverse events during the study. 
One patient in the alendronate group had an esoph-
ageal ulcer. Three patients in the alendronate group 
had hypercalcemia, as compared with seven in the 
alfacalcidol group (hazard ratio, 0.45; 95 percent 
confidence interval, 0.12 to 1.71). In one patient 
in the alendronate group, calcium supplementation 
was stopped because of hypercalcemia, but no re-
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Figure 3. Changes in Levels of Serum Calcium Corrected 
for Albumin, Serum Parathyroid Hormone, Serum P1CP, 
and Urinary N-Telopeptide.
At 18 months, the mean differences between the alen-
dronate and alfacalcidol groups in the serum calcium 
level were −0.24 mg per deciliter (−0.06 mmol per liter) 
(95 percent confidence interval, −0.44 to –0.08 [−0.11 
to −0.02]) (Panel A); in the serum parathyroid hormone 
level, 2.4 pmol per liter (95 percent confidence interval, 
1.7 to 3.1) (Panel B); in the serum P1CP level, −400 pmol 
per liter (95 percent confidence interval, −568 to −111) 
(Panel C); and in the urinary N-telopeptide level, −22 
nmol per liter (95 percent confidence interval, −146 to 
101) (Panel D). The I bars represent SE. To convert 
  values for calcium to milligrams per deciliter, divide 
by 0.250.
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duction in the dose of alfacalcidol or placebo was 
necessary, because the serum calcium level nor-
malized. There was no report of thyroid or renal 
dysfunction during the study. In the alfacalcidol 
group, one patient withdrew from the study be-
cause of congestive heart failure and another died 
of a cerebrovascular accident.
Discussion
In patients with a rheumatic disease in whom glu-
cocorticoid therapy was initiated at a daily dose of 
at least 7.5 mg of prednisone or the equivalent and 
who were treated for 18 months with alendronate 
or alfacalcidol, we found a significant difference 
of 4.0 percent in bone mineral density of the lum-
bar spine favoring alendronate. Similar results were 
observed for bone mineral density of the femoral 
neck and total hip. These differences result from 
an increase in bone mineral density in patients re-
ceiving alendronate and a decrease in those re-
ceiving alfacalcidol.
One third of the patients in our study had rheu-
matoid arthritis, one third had polymyalgia rheu-
matica, and one third had another rheumatic dis-
ease. A previous study indicated that patients with 
rheumatoid arthritis who received glucocorticoids 
had twice the number of vertebral deformities as 
did such patients not receiving glucocorticoids.1 
In patients with polymyalgia rheumatica receiving 
low-dose glucocorticoids, accelerated bone loss 
has been demonstrated in the lumbar spine.28
Table 2. Adverse Events.*
Adverse Event
Alendronate
(N = 98)
Alfacalcidol
(N = 100) Hazard Ratio (95% CI)
no. of patients
≥1 Adverse events 68 67 1.02 (0.79–1.33)
Related to study drug† 21 14 1.44 (0.77–2.69)
Withdrawals because of adverse event
Related to study drug† 3 1 3.00 (0.32–28.40)
Related to other adverse event 3 6 0.53 (0.14–2.04)
Death‡ 2 1 2.02 (0.12–21.90)
Gastrointestinal adverse event 35 52 0.77 (0.54–1.10)
Dyspepsia 7 8 0.90 (0.34–2.39)
Diarrhea 3 7 0.45 (0.12–1.71)
Nausea 2 8 0.27 (0.06–1.24)
Abdominal pain 5 4 1.26 (0.35–4.57)
Other symptoms 18 25 0.78 (0.45–1.35)
Other adverse events 18 17 1.07 (0.58–1.97)
Skin disorder 11 9 1.22 (0.53–2.83)
Headache 7 8 0.90 (0.34–2.39)
Laboratory adverse events 47 44 1.06 (0.75–1.49)
Hypocalcemia (calcium <8.8 mg/dl [2.2 mmol/liter]) 36 21 1.55 (0.96–2.50)
Increase in creatinine >0.2 mg/dl (22 μmol/liter)§ 8 16 0.55 (0.24–1.23)
Hypercalcemia (calcium >10.8 mg/dl [2.7 mmol/liter]) 3 7 0.45 (0.12–1.71)
* Patients could have had one or more adverse events, which were reported by the patients themselves or by investiga-
tors. No data were available about adverse events for two patients (one in each group).
† The adverse event was either probably or definitely attributable to the use of a study medication.
‡ The cause of death was not related to the use of a study medication. In the alendronate group, one patient died from a 
perforated sigmoid colon due to diverticulitis, and one patient died from non-Hodgkin’s lymphoma. In the alfacalcidol 
group, one patient died from a cerebrovascular accident.
§ The serum creatinine level was compared with the previous measurement.
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Alfacalcidol has dual effects on bone. It in-
creases bone formation by the stimulation of os-
teoblasts and has an antiresorptive effect.13 Alfa-
calcidol suppresses the synthesis and release of 
parathyroid hormone and increases the intesti-
nal absorption and reabsorption of calcium in the 
distal renal tubules.29 In rats, active vitamin D3 
metabolites have been shown to improve the mi-
croarchitecture and strength of bone.13,30 All these 
properties could be beneficial in the prevention of 
glucocorticoid-induced osteoporosis. Indeed, ac-
tive vitamin D3 metabolites were more effective 
in preserving bone mineral density and decreasing 
the risk of vertebral deformities during glucocor-
ticoid therapy than was no treatment, placebo, or 
treatment with vitamin D3, calcium, or both.16 
Bisphosphonates such as alendronate are effective 
in the treatment and prevention of glucocorticoid-
induced osteoporosis.18-20 Only one study (with 
an open-label design) in patients with a rheu-
matic disease who were receiving glucocorti-
coids has directly compared the effect of alen-
dronate with that of calcitriol; in that study, 
alendronate was superior in the prevention of glu-
cocorticoid-induced osteoporosis.21
In our study, levels of bone markers suggest 
stimulation of bone formation in the alfacalcidol 
group, but the increase in serum P1CP levels was 
probably caused, in part, by the gradual decrease 
in the glucocorticoid dose during the study, which 
probably caused progressively less inhibition of 
osteoblast function by glucocorticoids. Despite 
this trend of stimulation of bone formation, the 
bone mineral density in the alfacalcidol group de-
creased. Although more new vertebral deformities 
occurred in this group than in the group receiv-
ing alendronate, the difference was not signifi-
cant. In the alendronate group, levels of urinary 
N-telopeptide decreased, indicating a reduction 
in bone resorption, coupled with a small decrease 
in the serum P1CP level. The serum parathyroid 
hormone level increased in this group, probably 
owing to a decrease in the serum calcium level due 
to the inhibition of bone resorption. Another ex-
planation could be that there were more patients 
with a deficiency of 25-hydroxyvitamin D than 
were defined by our cutoff serum level of 30 nmol 
per liter. We believe that with the use of alendro-
nate, adequate supplementation with calcium and 
vitamin D3 is required.
Bone mineral density in the alendronate group 
increased, as compared with that in the alfacal-
cidol group, and fewer patients in the alendronate 
group had new vertebral deformities, although the 
difference was not significant. Thus, alendronate 
may inhibit bone loss in glucocorticoid-induced 
osteoporosis more effectively than does alfacal-
cidol. The benefits of bisphosphonates in gluco-
corticoid-induced osteoporosis have been ascribed 
primarily to their antiresorptive effect and second-
arily to possible inhibition of apoptosis of osteo-
blasts.31,32
There were few side effects of either treatment. 
Transient hypercalcemia developed in only seven 
patients receiving alfacalcidol. Because of logistic 
difficulties, we did not perform 24-hour urinary 
calcium measurement, but hypercalciuria is often 
found in patients receiving active vitamin D3 me-
tabolites.25 Therefore, in addition to the measure-
ment of serum calcium levels, urinary calcium 
monitoring may be necessary for safety reasons 
in patients receiving active vitamin D3.
In summary, our study indicates that alendro-
nate is more effective than alfacalcidol in the pre-
vention of glucocorticoid-induced bone loss.
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appendix
The following investigators, all in the Netherlands, also participated in the STOP study: Medical Center Alkmaar, Alkmaar — W. Swen; 
Outdoor Patient Center Buitenveldert, Amsterdam — G. Schardijn; Gelre Hospital, Apeldoorn — F. Eggelmeijer; Leyenburg Hospital, Den Haag — 
H. Ronday; Scheper Ziekenhuis, Emmen — H. Lim; Oosterschelde Hospital, Goes — P. de Sonnaville; Atrium Medical Center, Heerlen — H. Houben; 
Sint Antonius Hospital, Nieuwegein — E.J. ter Borg; Laurentius Hospital, Roermond — P. Jacobs; Sint Franciscus Hospital, Rotterdam — H. van Paas-
sen; Medical Center Rijnmond Zuid, Rotterdam — H. Markusse (deceased), A. Romme; Hospital Rivierenland, Tiel — K.J. Korff; Mesos Medical 
Center, Utrecht — J. Ehrlich; Zuwe Hofpoort Hospital, Woerden — M. van Lieshout, J. Macfarlane; Isala Hospital, Zwolle — S. Zanen.
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